<DOC>
	<DOC>NCT02401139</DOC>
	<brief_summary>This study is a Randomized Controlled Trial, investigating the safety and efficacy of administration of ketamine as a potential treatment for depression.</brief_summary>
	<brief_title>Ketamine Trial for the Treatment of Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Individuals will be eligible for enrolment on the basis of: major depressive disorder for at least three months duration an inadequate response to at least 2 adequate antidepressants MADRS â‰¥ 20 Patients will be excluded on the basis of: History of psychosis History of bipolar disorder Any unstable medical or neurologic condition Any Axis I disorder other than MDD judged to be primary presenting problem Planned major changes to psychotropic medication Significant risk of suicide Planned or probable use of ECT Age under 16 years, or 1617 years without parental consent Substance abuse or dependence in previous 6 months Any history of abuse of ketamine or phencyclidine Contraindication to the use of ketamine Planned use of ketamine Women of childbearing potential not taking reliable contraception Likely noncompliance with trial treatment Other condition judged by the treating clinician as likely to impact on the ability of the participant to complete the trial</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>